Moreover, Wolchok et al. demonstrated that in a clinical trial of patients with melanoma, concurrent PD-1 and CTLA-4 blockade resulted in a 53% response rate with significant tumor regression and a manageable safety profile—this response rate far exceeded anything previously encountered with anti-PD-1 or anti-CTLA-4 monotherapy [114]. Here, CTLA4 is linked to neoplasm.